PL2718316T3 - Polipeptydy - Google Patents
PolipeptydyInfo
- Publication number
- PL2718316T3 PL2718316T3 PL12729418T PL12729418T PL2718316T3 PL 2718316 T3 PL2718316 T3 PL 2718316T3 PL 12729418 T PL12729418 T PL 12729418T PL 12729418 T PL12729418 T PL 12729418T PL 2718316 T3 PL2718316 T3 PL 2718316T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169405 | 2011-06-10 | ||
| US201161496113P | 2011-06-13 | 2011-06-13 | |
| EP12729418.9A EP2718316B1 (en) | 2011-06-10 | 2012-06-08 | Polypeptides |
| PCT/EP2012/060900 WO2012168432A1 (en) | 2011-06-10 | 2012-06-08 | Polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2718316T3 true PL2718316T3 (pl) | 2020-06-29 |
Family
ID=47295518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12729418T PL2718316T3 (pl) | 2011-06-10 | 2012-06-08 | Polipeptydy |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8722849B2 (pl) |
| EP (3) | EP2718316B1 (pl) |
| JP (3) | JP6121992B2 (pl) |
| KR (1) | KR102066987B1 (pl) |
| CN (3) | CN103596973A (pl) |
| AU (1) | AU2012266269B2 (pl) |
| BR (1) | BR112013031268B1 (pl) |
| CA (1) | CA2838884C (pl) |
| ES (1) | ES2664509T3 (pl) |
| IL (1) | IL229258B (pl) |
| MX (1) | MX341324B (pl) |
| MY (1) | MY161773A (pl) |
| PL (1) | PL2718316T3 (pl) |
| RS (1) | RS59977B1 (pl) |
| RU (1) | RU2669999C2 (pl) |
| SI (1) | SI2718316T1 (pl) |
| WO (3) | WO2012168430A2 (pl) |
| ZA (1) | ZA201309174B (pl) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102066987B1 (ko) | 2011-06-10 | 2020-01-16 | 노보 노르디스크 에이/에스 | 폴리펩티드 |
| ES2640285T3 (es) * | 2012-04-19 | 2017-11-02 | Novo Nordisk A/S | Análogos de amilina humana |
| AR096440A1 (es) | 2013-05-28 | 2015-12-30 | Takeda Pharmaceuticals Co | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| WO2016034604A1 (en) * | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| CA2971721A1 (en) | 2014-12-23 | 2016-06-30 | Colgate-Palmolive Company | Oral care composition |
| CN105985995A (zh) * | 2015-01-29 | 2016-10-05 | 暨南大学 | 一种利用家蚕生物反应器生产普兰林肽(pa)的方法 |
| EA035791B1 (ru) * | 2015-03-18 | 2020-08-11 | Зилэнд Фарма А/С | Аналоги амилина |
| CN106554405B (zh) * | 2015-09-30 | 2020-04-24 | 深圳翰宇药业股份有限公司 | 一种多肽及其用途、制备方法 |
| CN106928086B (zh) | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| EP3467106B1 (en) | 2016-05-24 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Peptide compound |
| AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| HUE066356T2 (hu) | 2017-08-24 | 2024-07-28 | Novo Nordisk As | GLP-1 készítmények és alkalmazásaik |
| KR102911883B1 (ko) | 2018-10-11 | 2026-01-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 인간 아밀린 유사체 폴리펩타이드 및 사용 방법 |
| CN119455003A (zh) | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| CN113614101B (zh) | 2019-02-22 | 2024-07-16 | 洛约拉马利蒙特大学 | 淀粉样肽的变体 |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| PE20221575A1 (es) * | 2020-02-18 | 2022-10-06 | Novo Nordisk As | Formulaciones farmaceuticas |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
| IL300620B2 (en) | 2020-09-24 | 2025-12-01 | Gubra As | Ham15-52 analogues with improved amylin receptor (hamy3r) potency |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| MX2023011480A (es) | 2021-04-03 | 2023-12-06 | Ambrx Inc | Conjugados anticuerpo anti-her2-fármaco y usos de estos. |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| TWI876242B (zh) | 2021-12-13 | 2025-03-11 | 丹麥商諾佛 儂迪克股份有限公司 | 包括環糊精的醫藥調配物 |
| CN118973602A (zh) | 2022-03-30 | 2024-11-15 | 诺和诺德股份有限公司 | 配制方法 |
| EP4534553A1 (en) * | 2022-05-27 | 2025-04-09 | Hangzhou Sciwind Biosciences Co., Ltd. | Human amylin analog, and derivative and use thereof |
| MX2024005969A (es) | 2022-05-30 | 2024-06-11 | Zealand Pharma As | Formulaciones liquidas de analogos de amilina. |
| IL319599A (en) | 2022-09-19 | 2025-05-01 | Zealand Pharma As | Combination therapy |
| KR20250127104A (ko) * | 2022-12-22 | 2025-08-26 | 노보 노르디스크 에이/에스 | 아밀린 수용체 작용제 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| WO2024164776A1 (zh) * | 2023-02-10 | 2024-08-15 | 杭州先为达生物科技股份有限公司 | 多肽及其衍生物、组合物及其应用 |
| TW202500183A (zh) | 2023-06-15 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 包括環糊精的醫藥調配物 |
| TW202504913A (zh) | 2023-06-21 | 2025-02-01 | 丹麥商西蘭製藥公司 | 減重 |
| EP4731239A1 (en) | 2023-06-21 | 2026-04-29 | Zealand Pharma A/S | Analogues with improved properties |
| KR20260032481A (ko) | 2023-06-30 | 2026-03-09 | 질랜드 파마 에이/에스 | 병용 요법 |
| WO2025114501A1 (en) | 2023-11-30 | 2025-06-05 | Novo Nordisk A/S | Tri-agonists of the glp-1, gip, and amylin receptors |
| WO2025160082A1 (en) * | 2024-01-23 | 2025-07-31 | Viking Therapeutics, Inc. | Amylin analogs |
| TW202545982A (zh) * | 2024-02-07 | 2025-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 胰島澱粉樣多肽類似物及其醫藥用途 |
| WO2025172606A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4721760A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603079A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603080A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684802A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172605A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684801A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4721761A1 (en) | 2024-10-07 | 2026-04-08 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| EP1053001B1 (en) | 1998-02-13 | 2010-12-15 | Amylin Pharmaceuticals, Inc. | Novel mixed amylin activity compounds |
| WO1999057147A1 (fr) * | 1998-04-30 | 1999-11-11 | Kirin Brewery Company, Limited | Mutants de la thrombopoietine humaine |
| AU4930299A (en) * | 1998-07-31 | 2000-02-21 | Kirin Beer Kabushiki Kaisha | Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005097825A2 (en) * | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー/エス | アミリン誘導体 |
| CN101578102B (zh) * | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| CN102076353A (zh) | 2008-06-25 | 2011-05-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 |
| WO2010046357A1 (en) | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| EP2504355B1 (en) | 2009-11-25 | 2015-07-22 | Novo Nordisk A/S | Method for making polypeptides |
| KR102066987B1 (ko) | 2011-06-10 | 2020-01-16 | 노보 노르디스크 에이/에스 | 폴리펩티드 |
-
2012
- 2012-06-08 KR KR1020137034732A patent/KR102066987B1/ko active Active
- 2012-06-08 WO PCT/EP2012/060897 patent/WO2012168430A2/en not_active Ceased
- 2012-06-08 CN CN201280028644.0A patent/CN103596973A/zh active Pending
- 2012-06-08 RU RU2013156937A patent/RU2669999C2/ru active
- 2012-06-08 BR BR112013031268-8A patent/BR112013031268B1/pt active IP Right Grant
- 2012-06-08 SI SI201231728T patent/SI2718316T1/sl unknown
- 2012-06-08 CA CA2838884A patent/CA2838884C/en active Active
- 2012-06-08 US US13/491,885 patent/US8722849B2/en active Active
- 2012-06-08 EP EP12729418.9A patent/EP2718316B1/en active Active
- 2012-06-08 EP EP12729416.3A patent/EP2718314A2/en not_active Withdrawn
- 2012-06-08 CN CN201280028554.1A patent/CN103596972B/zh active Active
- 2012-06-08 JP JP2014514091A patent/JP6121992B2/ja active Active
- 2012-06-08 AU AU2012266269A patent/AU2012266269B2/en active Active
- 2012-06-08 MY MYPI2013004133A patent/MY161773A/en unknown
- 2012-06-08 MX MX2013013913A patent/MX341324B/es active IP Right Grant
- 2012-06-08 ES ES12729417.1T patent/ES2664509T3/es active Active
- 2012-06-08 US US13/491,883 patent/US8741836B2/en active Active
- 2012-06-08 US US13/491,880 patent/US8575090B2/en active Active
- 2012-06-08 PL PL12729418T patent/PL2718316T3/pl unknown
- 2012-06-08 JP JP2014514092A patent/JP6247205B2/ja active Active
- 2012-06-08 JP JP2014514090A patent/JP2014519509A/ja active Pending
- 2012-06-08 WO PCT/EP2012/060900 patent/WO2012168432A1/en not_active Ceased
- 2012-06-08 EP EP12729417.1A patent/EP2718315B1/en active Active
- 2012-06-08 CN CN201280028642.1A patent/CN103649115B/zh active Active
- 2012-06-08 WO PCT/EP2012/060899 patent/WO2012168431A2/en not_active Ceased
- 2012-06-08 RS RS20200191A patent/RS59977B1/sr unknown
-
2013
- 2013-09-26 US US14/038,265 patent/US9029325B2/en active Active
- 2013-11-05 IL IL22925813A patent/IL229258B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09174A patent/ZA201309174B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291571A (en) | cx3cr1 binding polypeptides | |
| ZA201309174B (en) | Polypeptides | |
| DK3505720T3 (en) | Cementering under styret tryk | |
| ZA201300994B (en) | Polypeptides | |
| GB201220474D0 (en) | Polypeptides | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| GB201111183D0 (en) | Peptide | |
| GB201115910D0 (en) | Peptides | |
| LT2699681T (lt) | Hipoalergenas | |
| PT2776382T (pt) | Folatos de 18f-sacárido | |
| PL2745011T3 (pl) | Zespół motopompy | |
| GB2491829B (en) | J-cup | |
| GB201210292D0 (en) | Hydraulischer antrieb | |
| HUE047406T2 (hu) | Polipeptidek | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| GB201112849D0 (en) | Polypeptide | |
| GB201112985D0 (en) | Polypeptide | |
| GB201106130D0 (en) | Polypeptide | |
| GB201115014D0 (en) | Peptides | |
| GB201103961D0 (en) | Binding polypeptides | |
| GB201103968D0 (en) | Detecting polypeptides | |
| AP00723S1 (en) | Autorickshaw | |
| GB201118263D0 (en) | Corcost-CH001 |